Chemotherapy Drug Increases Kidney Injury in Mouse Model of Lung Cancer

Article title: Lung cancer-kidney cross talk induces kidney injury, interstitial fibrosis, and enhances cisplatin-induced nephrotoxicity Authors: Andrew Orwick, Sophia M. Sears, Cierra N. Sharp, Mark A. Doll, Parag P. Shah, Levi J. Beverly, Leah J. Siskind From the authors: “This…

MD Anderson Research Highlights for March 29, 2023

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).

Ochsner Health Advances Precision Medicine, Becomes National Leader in Universal Genomic Testing for Chemotherapy

Ochsner Health is leading the way for precision medicine nationwide by becoming one of the first hospital systems to standardize genomic testing, significantly advancing ways in which care teams can treat cancer patients. This change helps providers determine individualized treatment by understanding how patients will react to certain drugs, thereby lowering risk of adverse side effects, improving patient experience, and bettering patient outcomes.

MD Anderson Research Highlights for March 8, 2023

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

Mouse study suggests new therapeutic strategy to reduce cardiovascular disease in cancer survivors

Researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York have discovered that common cancer treatments, such as radiotherapy or anthracycline drugs, cause long-term damage to heart tissue by activating a key inflammatory signaling pathway. The study, published December 19 in the Journal of Experimental Medicine (JEM), suggests that inhibiting this pathway could reduce the chances of cancer survivors suffering heart disease later in life.

Anti-sedative could alleviate cancer therapy side effects, study suggests

Researchers in China have discovered that inhibiting a protein called the GABAA receptor can protect intestinal stem cells from the toxic effects of chemotherapy and radiotherapy. The study, published September 20 in the Journal of Experimental Medicine (JEM), suggests that the FDA-approved anti-sedative flumazenil, which targets GABAA receptors, could alleviate some of the common gastrointestinal side effects, such as diarrhea and vomiting, induced by many cancer treatments.

NUS AI platform enables doctors to optimise personalised chemotherapy dose

A team of researchers from National University of Singapore, in collaboration with clinicians from the National University Cancer Institute, Singapore which is part of the National University Health System, has reported promising results in using CURATE.AI, an artificial intelligence tool that identifies and better allows clinicians to make optimal and personalised doses of chemotherapy for patients.

Chula Excellence Cancer Center collabs with medical specialists from various fields to enhance treatment capabilities.

Chula now has an Excellence Chulalongkorn Comprehensive Cancer Center bringing together medical specialists from various areas of expertise to attend to cancer patients using the latest academic and technological know-how to enhance the quality of life and the possibilities of being cured for patients of all types of cancer.

Stress-relief Music Therapy Can Also Effectively Relieve Pain

Medical results show that music therapy can lower blood pressure, relieve pain during chemotherapy and dialysis, as well as stimulate the elderly brain. The Faculty of Fine and Applied Arts, Chulalongkorn University is offering a Music Therapy Program aiming to heal the ever-increasing patients with various chronic diseases in society.

Study Shows Immunotherapy Drug Combination Improves Response in HER2-Negative Breast Cancer Including a Subset of Estrogen Receptor Positive Cancers

In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.

Atlantic Health System Physicians Co-Author 5 Studies, Presented at American Association for Cancer Research (AACR) Annual Meeting

Atlantic Health System Cancer Care physicians are co-authors of five original studies presented at this year’s AACR Annual Meeting, held virtually April 10-15 and May 17-21. The AACR meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers.

Targeting microRNAs could unmask hidden vulnerability in breast cancer stem cells

Researchers in Italy have identified a pair of microRNA molecules that help maintain a population of cancerous stem cells that drive the growth of breast cancers and initiate tumor relapse after treatment. The study, which will be published April 2 in the Journal of Cell Biology (JCB), reveals that targeting these microRNAs makes cancer stem cells more susceptible to some chemotherapies and could potentially improve the prognosis of patients with aggressive forms of breast cancer.

Regular Exercise May Protect Cardiovascular Cells during Chemotherapy

Marie Mclaughlin, MSc, from Edinburgh Napier University in Scotland, will present research on human endothelial cells treated with FEC-T, a chemotherapy regimen that combines four drugs (5 fluorouracil, epirubicin, cyclophosphamide and docetaxel). The researchers found that preconditioning the endothelial cells with serum (blood) from people who habitually exercise caused less cell death than samples that were treated with untrained serum (people who exercised less than 75 minutes per week). “Exercise preconditioning can provide protection against these detrimental effects in vitro,” Mclaughlin explained.

Exercise May Improve Effects of Radiation Therapy in Prostate Cancer

Cancer is the second leading cause of death around the world after heart disease. This week, researchers exploring the effects of exercise as a natural preventive tool and noninvasive treatment for cancer will present their work at the American Physiological Society (APS) Integrative Physiology of Exercise conference.

Accelerating Access to Breakthrough Cancer Therapies Leads Morristown Medical Center to Expand Infusion Center

Atlantic Health System has announced the opening of Morristown Medical Center’s new state-of-the-art, patient-centered Infusion Center located in the Carol G. Simon Cancer Center. The first of three phases of expansion of New Jersey’s pre-eminent cancer center, the new unit was funded in large part by donations made by community members in support of the Foundation for Morristown Medical Center’s Growing Forward Campaign.

Chemotherapy Drug More Effective When Combined With Microbubbles

Hepatocellular carcinoma is usually treated by blocking the flow of blood to the tumor to induce cancer cell death, but the common treatment, transarterial chemoembolization, is invasive and too imprecise to be a local drug delivery method. Aiming to increase the precision, researchers at Tulane University created a treatment that involves vaporizing tiny droplets of perfluorocarbon, a common organic material composed of carbon and fluorine. The method of gas embolization is published in APL Bioengineering.

Structure of a Complex Enzyme That Protects Cells From DNA Damage Is Uncovered by Mount Sinai Researchers

A research team from Mount Sinai has unraveled for the first time the three-dimensional structure and mechanism of a complex enzyme that protects cells from constant DNA damage, opening the door to discovery of new therapeutics for the treatment of chemotherapy-resistant cancers.

Sylvester Comprehensive Cancer Center Urologist Leads Collaborative Study on Fertility Counseling Prior to Chemotherapy

For younger cancer patients, fertility counseling at the time of cancer diagnosis is important for making family planning decisions. Ranjith Ramasamy, M.D., a clinician and researcher at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, was the lead author of a new collaborative study, “Evaluation of Reported Fertility Preservation Counseling Before Chemotherapy Using the Quality Oncology Practice Initiative Survey,” published JAMA Network Open.

Breaking Research News from Annual Meeting of American Society of Clinical Oncology

Johns Hopkins Kimmel Cancer Center thoracic cancer and cancer genomics experts reported promising new findings and studies in mesothelioma, lung cancer and melanoma at the annual meeting of the American Society of Clinical Oncology (ASCO), the world’s leading professional organization for physicians and oncology professionals caring for cancer patients.

MSK: Cancer Isn’t Sheltering in Place

As the height of the COVID-19 outbreak in New York City and the Tri-State area begins to subside, Memorial Sloan Kettering Cancer Center oncologists are urging patients to schedule cancer screenings and treatments now – as the long-term toll of missed diagnoses and delayed treatments could be devastating for patients and their loved ones across the region and the country.

Combination of Chemo and Immunotherapy Is Shown to Work Against Metastatic Bladder Cancer

A clinical trial led by Mount Sinai researchers has showed for the first time that combining chemotherapy and immunotherapy can slow down metastatic bladder cancer. The trial also showed that immunotherapy alone may be an option for a subset of patients with metastatic bladder cancer if their tumor expresses a high level of a protein called PD-L1 according to the study, published in The Lancet in May.

Immunotherapy Treatment Immediately After Chemotherapy Significantly Slows Metastatic Bladder Cancer Progression

Using immunotherapy immediately after chemotherapy treatment in patients with metastatic bladder cancer significantly slowed the progression of the cancer, according to results of a clinical trial led by Mount Sinai researchers published in the Journal of Clinical Oncology in April.